Targeting a specific pathway to improve treatment for complex sarcomas
Project 2: Targeting the Hippo Pathway in Genetically Complex Sarcomas
This study is looking at new treatments for four tough types of sarcoma by exploring how these tumors grow and survive, and it will test a new drug that could help improve outcomes for patients dealing with these cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10848815 on NIH RePORTER |
What this research studies
This research focuses on developing targeted therapies for four aggressive types of sarcoma: well-differentiated liposarcoma, dedifferentiated liposarcoma, myxofibrosarcoma, and undifferentiated pleomorphic sarcoma. The study investigates the Hippo pathway's role in these cancers, which are known for their complexity and poor treatment options. Researchers aim to understand how these tumors rely on specific proteins for growth and survival, and they will test a new drug that inhibits a key protein involved in this process. By targeting these pathways, the research seeks to improve outcomes for patients with advanced sarcoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with well-differentiated liposarcoma, dedifferentiated liposarcoma, myxofibrosarcoma, or undifferentiated pleomorphic sarcoma.
Not a fit: Patients with sarcomas that do not fall into these specific subtypes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from aggressive sarcomas, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Singer, Samuel — Sloan-Kettering Inst Can Research
- Study coordinator: Singer, Samuel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.